01 December 2015

1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
Futura Medical plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights  
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached  
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments  
An event changing the breakdown of voting rights  
Other (please specify): Revised Transparency Directive x
3. Full name of person(s) subject to the
notification obligation:
Henderson Group plc
4. Full name of shareholder(s)
(if different from 3.):
 
5. Date of the transaction and date on which the threshold is crossed orreached: 26 November 2015
6. Date on which issuer notified: 30 November 2015
7. Threshold(s) that is/are crossed or reached: Above 19%

8. Notified details:
A: Voting rights attached to shares
Class/type of
shares

if possible using
the ISIN CODE
Situation previous
to the triggering
transaction
Resulting situation after the triggering transaction
Number
of
Shares
Number
of
Voting
Rights
Number
of shares
Number of voting
rights
% of voting rights
Direct Direct Indirect Direct Indirect
Ordinary

GB0033278473
18,848,039 18,848,039     19,098,039   19.28%

B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument Expiration date Exercise/ Conversion Period Number of voting rights that may be acquired if the instrument is exercised/ converted. % of voting rights
         

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument Exercise price Expiration date Exercise/
Conversion period
Number of voting rights instrument refers to % of voting rights
          Nominal Delta
   

Total (A+B+C)
Number of voting rights Percentage of voting rights
19.28% 19.28%

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
See Appendix 1 below.
 
Proxy Voting:
10. Name of the proxy holder:  
11. Number of voting rights proxy holder will cease to hold:  
12. Date on which proxy holder will cease to hold voting rights:  
 
13. Additional information: Revised Transparency Directive notification.

This disclosure has been calculated based on total voting rights of 99,022,600.
14. Contact name: HGIThresholdDisclosures@henderson.com
15. Contact telephone number: 020 7818 5738 / 4184

Annex 1: Information in relation to the person subject to the notification obligation (please tick the applicable box):

[ ] Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

[X] Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:

Namexv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Henderson Group plc, Henderson Group Holdings Asset Management Limited, HGI Asset Management Group Limited, Henderson Global Group Limited, Henderson Holdings Group Limited, HGI Group Limited, Henderson Global Investors (Holdings) Limited, AlphaGen Capital Limited Below 5% 0 Below 5%




Henderson Group plc, Henderson Group Holdings Asset Management Limited, HGI Asset Management Group Limited, Henderson Global Group Limited, Henderson Holdings Group Limited, HGI Group Limited, Henderson Global Investors (Holdings) Limited, Henderson Global Investors Limited 15.10% 0 15.10%

 

For further information please contact:

Futura Medical plc
James Barder, Chief Executive
+44 (0) 1483 685 670
james.barder@futuramedical.com
www.futuramedical.com

Nominated Adviser:
N+1 Singer
Aubrey Powell / Liz Yong / Thomas Smale
Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Buchanan Communications Limited
Mark Court / Sophie Cowles /
Stephanie Watson
Tel: +44 (0) 20 7466 5000